Chimeric molecules to modulate gene expression

ABSTRACT

The present invention provides a chimeric molecule including a base-pairing segment that binds specifically to a single-stranded nucleic acid molecule; and a moiety that modulates splicing or translation. The invention also provides a chimeric molecule including a base-pairing segment that binds specifically to a double-stranded nucleic acid molecule; and a peptide that modulates transcription, wherein the peptide comprises up to about one hundred amino acid residues.

This application asserts the priority of provisional U.S. applicationNo. 60/304,182 filed Nov. 9, 2000, which is incorporated by reference inits entirety.

This work was supported by the following grants: GM42699 and CA13106from the N.I.H. The government has certain rights to this invention.

BACKGROUND OF THE INVENTION

Gene expression is the process by which the protein product of a gene ismade. Included in gene expression are the steps of transcription,splicing and translation. Transcription is the process by whichinformation from double-stranded DNA is converted into itssingle-stranded RNA equivalent, termed a pre-mRNA transcript. Splicingis the process by which introns of the pre-mRNA transcript are removed;and the remaining exons are joined to form mRNA. Translation is thesynthesis of a protein using the “mRNA as a template.

The ability to modulate gene expression is a valuable too! both forresearch and therapeutic purposes. For example, a researcher may wish tomodulate the activity of a particular gene so as to identify thefunction of the gene, the effect the gene product's cellularconcentration has on the function of the cell, or other cellularcharacteristics. With respect to therapeutics, one may wish to modulategene expression in order to increase the production of certain proteinsthat may not be produced, or are produced at low levels, by the nativegene. The proteins may not be produced at sufficient levels due to adisease state or a genetic mutation.

Attempts have been made to modulate gene expression at the level oftranscription. For example, Dervan et al. describe an artificialtranscription factor. (Dervan et al., PNAS 97: 3930-3935.) The factorconsists of a DNA-binding polyamide tethered to a peptidetranscriptional activation domain. The polyamide contains a total ofeight N-methyhmidazole and N-methylpyrrole amino acids in the form of ahairpin structure. This structure results in the amino acids beingside-by-side to form four pairs. The possible pairing types describedare an imidazole paired with a pyrrole, and a pyrrole paired with apyrrole.

The polyamide binds to the minor groove of a DNA molecule via hydrogenbonds. The DNA-binding specificity depends on the type of the amino acidpairing.

A pairing of imidazole opposite pyrrole targets a G•C base pair, whereaspyrrole opposite imidazole targets a C•G base pair. A pyrrole/pyrrolecombination is degenerate and targets both Y•A and A•T base pairs.

The method for modulating gene expression described by Dervan et al. hasseveral limitations. For example, the DNA-binding hairpin polyamidesdescribed by Dervan et al. contain eight amides. Accordingly, thesepolyamides can be inserted between four nucleic acid base pairs of a DNAmolecule. A series of such a length is too short to allow for binding ofhigh specificity. For example, a series of at least ten to twenty basesare necessary in order to target a unique natural DNA sequence inprokaryotes and eukaryotes. Seventeen to eighteen bases are necessary totarget a unique sequence in the human genome.

In addition to the insufficient length of the Dervan et al. polyamides,binding of these polyamides are not as precise as would result fromWatson-Crick base-pairing. For example, the polyamides cannotdistinguish between AT and TA base pairs. This degeneracy furtherdecreases the specificity by which the Dervan et al. polyamides can bindto DNA.

Another limitation in the method of Dervan et al. is that the bindingpolyamides can only bind to double-stranded DNA. However, the modulationof splicing and translation both involve single-stranded RNAs.Accordingly, transcription is the only step of gene expression that canbe modulated by the method of Dervan et al. Splicing and translationcannot be modulated by the method of Dervan et al.

Another attempt to modulate gene expression at the level oftranscription is disclosed by Ecker et al. (U.S. Pat. No. 5,986,053). Inparticular, Ecker et al. disclose “conjugates” which are peptide nucleicacids (PNAs) conjugated to proteins. The proteins are transcriptionfactors.

The method for modulating gene expression described by Ecker et al. hasseveral limitations. For example, since transcription factors containanywhere from about one hundred fifty to over a thousand residues, the“conjugates” disclosed by Ecker et al. are difficult to synthesize. Thelength of these “conjugates” also renders in vivo delivery and cellularuptake difficult. Consequently, the value of these “conjugates” astherapeutic agents is questionable.

Another limitation of the method of Ecker et al. for modulating geneexpression is that the only modulation contemplated is at the level oftranscription. Ecker et al. does not address the splicing andtranslation steps of gene expression.

The object of the present invention is to provide molecules thatmodulate splicing and/or translation. Additionally, the object of theinvention is to modulate transcription with molecules which bind withhigh specificity to double-stranded nucleic acid molecules and whichprovide ease of synthesis and delivery.

SUMMARY

These and other objects, as would be apparent to those skilled in theart, have been achieved by providing chimeric molecules which comprise abase-pairing segment that binds specifically to a single-strandednucleic acid molecule, and a moiety that modulates splicing ortranslation. In one embodiment, the invention relates to a method formodulating splicing and translation. The method comprises contacting asingle-stranded nucleic acid molecule with the chimeric molecule wherebythe binding of the base-pairing segment allows the moiety to modulatesplicing and translation. In another embodiment, the invention relatesto a method to correct defective splicing of a pre-mRNA transcriptduring pre-mRNA splicing. The method comprises contacting the pre-mRNAtranscript with the chimeric molecules whereby the binding of thebase-pairing segment allows the moiety to correct defective splicing.

In a third embodiment, the invention relates to chimeric molecules whichcomprise a base-pairing segment that binds specifically to adouble-stranded nucleic acid molecule, and a peptide that modulatestranscription, wherein the peptide comprises up to about one hundredamino acid residues. In a fourth embodiment, the invention relates to amethod for modulating transcription. The method comprises contacting adouble-stranded nucleic acid molecule with the chimeric molecule,whereby the binding of the base-pairing segment allows the peptide tomodulate transcription.

This invention also provides a method of making chimeric molecules thatmodulate gene expression The method comprises covalently bonding abase-pairing segment that binds specifically to a nucleic acid molecule,and a moiety that modulates gene expression.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a model of SF2/ASF-dependent exon 7 inclusion in SMN1 andSMN2. Binding of SF2/ASF to its cognate heptamer ESE in SMN1 exon 7(top) promotes exon definition, such that exon 7 is constitutivelyincluded, allowing for translation of full-length SMN protein. The C6Tchange in SMN2 exon 7 (bottom) prevents efficient SF2/ASF binding to thecorresponding heptamer. Exon 7 is thus mostly skipped, resulting in theproduction of defective SMNΔ7 protein. Other ESEs in the exon canmediate weak exon inclusion even in the absence of the SF2/ASF motif,probably through binding of other SR or SR-like proteins, which mayinclude hTra2β1. Partial inclusion of SMN2 exon 7 generates a smallamount of full-length SMN protein, identical to that encoded by the SMN1gene. Exons are represented as boxes and introns as lines. The gray boxindicates a region of exon 7 encoding the last 16 amino acids of the SMNprotein, which are missing from SMNΔ7. The dark box in exon 8 representsthe last four amino acids of SMNΔ7, which are not present in SMN. Openboxes represent 3′ untranslated regions. The hatched box in SMN1 exon 7marks the position of the SF2/ASF heptamer ESE. The correspondingheptamer is indicated below SMN2 exon 7, with position 6 in bold. Thedark oval denotes SF2/ASF and open ovals represent SR or SR-likeproteins. Arrows denote promotion of exon definition and chevronsindicate splicing patterns. Line thicknesses are indicative of relativesplicing efficiency. The percent values refer to the extent of exon 7inclusion in vivo. The diagrams of SMN and SMNΔ7 proteins illustrate thedifferent C-terminal domains. For simplicity, other SMN isoforms are notconsidered in this model. Drawings are not to scale.

FIG. 2 is a diagram showing theoretical interactions mediated byESE-bound SR proteins. ESE-bound SR proteins participate inprotein-protein interactions to recruit spliceosome components to theadjacent intron elements during the earliest stages of spliceosomeassembly. For example, the RS domain of SR proteins is thought tocontact the RS domain of U2AF³⁵, indirectly facilitating binding of thelarge U2AF subunit, U2AF⁶⁵, to the 3′ splice site poly-pyriridine tract.U2AF⁶⁵, in turn, is known to facilitate binding of the U2 snRNP to thebranch site via base pairing between U2 sRNA and the branch siteelement. SR proteins bound to exonic enhancers are also thought tofacilitate binding of U1 snRNP at the downstream 5′ splice site, exceptin the case of 3′ terminal exons, for which an interplay betweensplicing and 3′ end processing has been well documented. Ail theseinteractions are part of the process of exon definition, by whichspliceosomal components initially identify exon-intron boundariescorrectly, despite the very large size of some introns and thedegeneracy of the splice site signals. The interaction between SRproteins and U1 snRNP again appears to be mediated by the SR protein RSdomain, and, on the U1 snRNP side, by a related domain present in the70K polypeptide.

FIG. 3 is a diagram showing the motifs recognized by four SR proteins,displaying each nucleotide with a size proportional to its frequency atthat position of the consensus. These motifs define sequences thatfunction as exonic splicing enhancers in the presence of the cognate SRprotein.

FIG. 4 shows the time course results of an in vitro splicing assay usinga three-exon minigene and shortened versions of the introns of BRCA1.Splicing of the wild type (BR wt) and mutant (BR NL) transcripts in HeLanuclear extract reproduced the in vivo effect of the mutation on exon 18inclusion.

FIG. 5 shows a structural representation of a PNA-RNA hybrid.

FIG. 6 is a diagram showing a PNA-peptide targeted to BRCA1 pre-mRNAtranscript. The PNA is positioned one nucleotide downstream of themutation at exonic position +6 in BRCA1 exon 18, so it can hybridizeequivalently to wild-type and mutant sequences.

FIG. 7 shows effects of PNA-RS and control compounds on in vitrosplicing of BRCA1 pre-mRNA. The products of splicing were analyzed bydenaturing PAGE and autoradiography (top). The percentage of exon 18inclusion was quantitated (bottom); the points on the curves are opensymbols for the mutant, and solid symbols for the wild-type. Thedose-response curves for each compound show that the PNA-peptide (BRPNA•RS) was effective at promoting exon 18 inclusion with pre-mRNAharboring the patient nonsense mutation at position +6 (NL mut).

FIG. 8 shows the dose-response of PNA-RS on BRCA1 in vitro splicing at 1and 3 mM magnesium. The C lanes show the input pre-mRNAs.

FIG. 9 is a graph showing the SR protein motif distribution in SMN1 andSMN2 exon 7. The 54-nt sequence of exon 7 in SMN1 (top) and SMN2(bottom) was searched with four nucleotide-frequency matrices derivedfrom pools of functional enhancer sequences selected iteratively invito. Motif scores reflect the extent of matching to a degenerateconsensus, adjusted for background nucleotide composition, and only thescores above the threshold for each SR protein are shown. Gray and blackbars represent SC35 and SF2/ASF high-score motifs, respectively. NoSRp40 or SRp55 high-score motifs are present in exon 7. The height ofeach bar indicates the score value, the position along the x axisindicates its location along the exon, and the width of the barrepresents the length of the motif. The C at position +6 in SMN1 ishighlighted. The T at the same position in SAN2 causes both SF2/ASF andSC35 scores to fall below threshold (3.76 to 0.81 and 3.87 to 2.14,respectively). Thresholds and maximal values are different for differentSR proteins. The horizontal lines below the exon sequence mark thelocations of putative exonic splicing enhancers (SE1, SE2, and SE3,respectively).

FIG. 10 is a graph showing the effect of point mutations on calculatedSC35 and SF2/ASF motif scores. The first 12 nucleotides of exon 7 areshown, with the mutated positions +6 and +11 highlighted. The gray andblack horizontal bars indicate the position of the SC35 and SF2/ASFmotifs, respectively. The SF2/ASF consensus heptamer motif is aligned atthe top. The effect of the point mutations used in transfectionexperiments on the calculated SC35 and SF2/ASF motif scores is shown onthe right (high scores in black; sub-threshold scores in gray).

FIG. 11 illustrates that exon 7 skipping correlates with disruption ofthe proximal SF2/ASP heptamer motif. Semi-quantitative [α-³²P]dATP-labeled RT-PCR analysis of transient expression of SMN minigenes.The products corresponding to exon 7 skipping and inclusion areindicated. The A11G suppressor mutation that reconstitutes an SF2/ASPhigh-score motif (lanes 4 and 6) restores correct splicing when themutation at position +6 causes exon skipping (lanes 3 and 5).

FIG. 12 is a diagram showing a PNA-peptide targeted to SMN2 exon 7.

FIG. 13 is a graph showing the high-score SR protein motifs in BRCA1exon 18. Motif scores reflect the extent of matching to a degenerateconsensus, and only the scores above the threshold for each SR proteinare shown. High-score motifs are shown in black for SF2/ASF, dark greyfor SC35, light grey for SRp40, and white for SRp55. The width of eachbar reflects the length of the motif (6, 7, or 8 nt), the placement ofeach bar along the x axis indicates the position of a motif along thewild-type exon DNA sequence, and the height of the bar shows thenumerical score on the y axis.

FIG. 14 shows the results of in vitro splicing of BRCA1 minigenetranscripts. The exon-skipping phenotype of a nonsense mutation isreproduced. Wild-type (WT, lane 1) and nonsense mutant with low SF2/ASFscore (NL, lane 2) radiolabeled transcripts were spliced in HeLa cellnuclear extract, and the products of the reaction were analyzed bydenaturing PAGE and autoradiography. The identity of each band isindicated schematically on the right. Exons 17 and 19 are shown as greyboxes, exon 18 as a white box, and the shortened introns as lines. Thearrows indicate the mRNAs generated by exon 18 inclusion or skipping.

FIG. 15 illustrates that exon skipping correlates with the SF2/ASFenhancer motif score and not with reading frame disruption. FIG. 15 ashows a diagram of the in vitro-transcribed portions of wild-type andmutant BRCA1 minigenes. The relevant portion of the exon 18 sequence isshown above the diagram, beginning at position 1 and with the tripletgrouping indicating the reading frame. The heptamer sequencecorresponding to the first SF2/ASF motif in FIG. 13 is highlighted. Themutated nucleotides are shown in lowercase, and the in-frame nonsensecodons are underlined. WT—wild-type; NL—original nonsense mutant with alow SF2/ASF motif score; NH—nonsense mutant with a high score;ML—missense mutant with a low score. The calculated scores for thehighlighted heptamers are shown on the right. The sizes of the exons andtruncated introns, including 5 nt of T7 sequence and 10 nt of intron 19,are shown below the diagram WT, NL, NH, and NE pre-mRNAs were spliced invitro as in FIG. 14. The intensities of the mRNA bands arising from exon18 inclusion or skipping were measured, and the percent inclusion on amolar basis was calculated and is shown in FIG. 15 b.

FIG. 16 illustrates the SMN1 SF2/ASF heptamer motif is a bona fide ESE.a.) BRCA1 minigenes used for in vitro transcription and splicing. Therelevant portion of BRCA1 exon 18 is shown above the diagram, startingwith position +1 of each sequence. The calculated SF2/ASF motif scorescorresponding to the highlighted heptamers are indicated for eachminigene (high scores in black; sub-threshold scores in gray). Thehigh-score SF2/ASF ESE in the BRCA1 minigene (BR-WT) was replaced by theSF2/ASF heptamer from SMN1, or by the corresponding heptamer from SMN2(6CT). The pre-mRNA containing a natural BRCA1 nonsense mutation(E1694X) that abrogates an SF2/ASF-dependent ESE (BR-NL) is also shown.b.) The SF2/ASF heptamer motif from SMN1 promotes exon inclusion in aheterologous context (BRCA1 exon 18). The four indicated BRCA1-derivedpre-mRNAs were spliced in HeLa cell nuclear extract for 4 hours. Theidentity of each band is indicated schematically on the left. The sizesof pre-mRNA, exon-18-included and exon-18-skipped mRNAs are 488, 222 and144 nt, respectively. Singly-spliced mRNAs migrate at 352 and 358 nt.Exons 17 and 19 are shown as light boxes, exon 18 as a dark box, andshortened introns as lines.

FIG. 17 illustrates that SF2/ASF promotes SMN1 exon 7 inclusion in vito.a.) SMN minigenes used for in vitro transcription and splicing. Therelevant portion of SMN1 exon 7 is shown above the diagram, startingwith position +1 of each sequence. The calculated SF2/ASF motif scorescorresponding to the highlighted heptamers are indicated for eachminigene (high scores in black; sub-threshold score in gray). Theminigenes are derivatives of those used in transfections, with smallerintron 6 and exon 8 to increase RNA stability and transcription andsplicing efficiencies. b.) In vito splicing of S minigenes reproducesthe in vivo phenotype, and stimulation of exon 7 inclusion by SF2/ASFrequires an SF2/ASP high-score motif. The SMN1-derived pre-mRNAscorresponding to the wild type, or containing point mutations atposition +6 (C6T, corresponding to SMN2), +11 (A11G), or both(C6T/A11G), were incubated for 4 hours under splicing conditions in HeLanuclear extract (lanes 1-4), S100 extract alone (lanes 5-8), or S100extract complemented with 4 pmol of recombinant human SF2/ASP (lanes9-12) or SC35 (lanes 13-16). The pre-mRNAs, intermediates and maturemRNAs are indicated schematically; flanking exons 6 and 8 are shown asopen boxes, exon 7 as a gray box, and introns as lines. The sizes ofpre-mRNA, exon-7-included and exon-7-skipped rnRNAs are 910, 266 and 212nt, respectively. Singly-spliced mRNAs migrate at 466 and 710 nt. Thebands above the pre-mRNAs are the lariat intermediates. The structuresof the additional bands seen only in the presence of SC35 have not beendetermined.

FIG. 18 illustrates specific targeting of double-stranded DNA by bis-PNAin vitro.

-   -   a. Schematic representation of the bis-PNA bound to its dsDNA        target. The vertical lines represent Watson-Crick base pairing,        and the dots represent Hoogsteen base pairing. The PNA and        wild-type and mutant target sequences are shown. The three Os        denote three ethylene glycol linker residues.    -   b. Electrophoretic mobility-shift assay, using a radiolabeled        dsDNA target probe and unlabled PNA. Binding to the wild-type        sequence is PNA-dose-dependent. No binding to the mutant        sequence is observed, demonstrating the specificity.    -   c. Electrophoretic mobility-shift assay showing the        salt-dependence of binding.    -   d. Electrophoretic mobility-shift assay showing the pH        dependence of binding.        The dsDNA target is from the human y-globin promoter region, and        binding of a similar bis-PNA—containing pseudoisocytosine        instead of cytosine on the Hoogsteen strand—to the wild-type        sequence was described in Wang et al. (1999) Nucleic Acids Res.        27:2806-2813. Modified cytosine is desirable for optimal binding        at physiological pH.

FIG. 19 illustrates expression of BRCA1 in lymphoblast cell lines.Endogenous BRCA1 mRNA was analyzed by RT-PCR with primers specific forexons 17 and 19. In the wild-type cell line only full-length mRNA withexon 18 included is detected. In the heterozygous mutant cell line,equal levels of exon 18 inclusion (from the wild-type allele) andskipping (from the mutant allele) are detected.

DETAILED DESCRIPTION

The present invention provides chimeric molecules that include abase-pairing segment that binds specifically to a single-strandednucleic acid molecule, and a moiety that modulates gene expression.

The base-pairing segment comprises purine and/or pyrimidine bases. Thebases can be any naturally-occurring or modified purines andpyrimidines. Typically, the bases of the present invention are adenine,guanine, cytosine, thymidine and uracil.

These bases bind specifically to the bases of a target nucleic acidmolecule according to the Watson-Crick rules of base-pairing. As aconsequence of the precise nature of this binding, the base-pairingsegment can be designed to anneal with any predetermined sequence of anucleic acid molecule.

The bases can be modified, for example, by the addition of substituentsat one or more positions on the pyrimidines and purines. The addition ofsubstituents may or may not saturate any of the double bonds of thepyrimidines and purines. Examples of substituents include alkyl groups,nitro groups, halogens and hydrogens. The alkyl groups can be of anylength, preferably from one to six carbons. The alkyl groups can besaturated or unsaturated; and can be straight-chained, branched orcyclic. The halogens can be any of the halogens including, bromine,iodine, fluorine or chlorine.

Further modifications of the bases can be the interchanging and/orsubstitution of the atoms in the bases. For example, the positions of anitrogen atom and a carbon atom in the bases can be interchanged.Alternatively, a nitrogen atom can be substituted for a carbon atom; anoxygen atom can be substituted for a sulfur atom; or a nitrogen atom canbe substituted for an oxygen atom.

Another modification of the bases can be the fusing of an additionalring to the bases, such as an additional five or six membered ring. Thefused ring can carry various further groups.

Specific examples of modified bases include 2,6-diaminopurine,2-aminopurine, pseudoisocytosine, E-base, thiouracil, ribothymidine,dihydrouridine, pseudouridine, 4-thiouridine, 3-methlycytidine,5-methylcytidine, inosine, N⁶-methyladenosine, N⁶-isopentenyladenosine,7-methylguanosine, queuosine, wyosine, etheno-adenine, etheno-cytosine,5-methylcytosine, bromothymrine, azaadenine, azaguanine,2′-fluoro-uridine and 2′-fluoro-cytidine.

The bases are attached to a molecular backbone. The backbone comprisessugar or non-sugar units. The units are joined in any manner known inthe art.

In one embodiment, the units are joined by linking groups. Some examplesof linking groups include phosphate, thiophosphate, dithiophosphate,methylphosphate, amidate, phosphorothioate, methylphosphonate,phosphorodithioate and phosphorodiamidate groups.

Alternatively, the units can be directly joined together. An example ofa direct bond is the amide bond of, for example, a peptide.

The sugar backbone can comprise any naturally-occurring sugar. Examplesof naturally-occurring sugars include ribose and deoxyribose, forexample 2-deoxyribose.

A disadvantage of a base-pairing segment having naturally-occurringsugar units as the backbone is the possibility of cleavage by nucleases.Cleavage of the base-pairing segment can occur when the segment is in asingle-stranded state, or upon specifically binding to a nucleic acidmolecule.

Accordingly, it is preferable that the sugar units in the backbone aremodified so that the modified sugar backbone is resistant to cleavage.The sugars of the backbone can be modified in any manner that achievesthe desired cleavage resistance. Examples of modified sugars include2′-O-alkyl ribose, such as 2′-O-methyl ribose and 2′-O-allyl ribose.Preferably, the sugar units are joined by phosphate linkers. The sugarunits may be linked to each other by 3′-5′, 3′-3′ or 5′-5′ linkages.Additionally, 2′-5′ linkages are also possible if the 2′ OH is nototherwise modified.

The non-sugar backbone can comprise any non-sugar molecule to whichbases can be attached. Non-sugar backbones are known in the art.

In one embodiment, the non-sugar backbone comprises morpholine rings(tetrahydro-1,4-oxazine). (Loudon, G. M., Organic Chemistry, page 1178.)The resulting base-pairing segment is known as a morpholino oligo.(Summerton et al., Antisentse Nucleic Acid Drug Dev. 7:187-195 (1997).)The morpholine rings are preferably joined by non-ionicphosphorodiamidate groups. Modified morpholines known in the art canalso be used in the present invention. An example of a portion of amorpholino oligo is shown below, wherein “B” represents a base asdescribed above.

In another embodiment, the non-sugar backbone comprises modified, orunmodified, amino acid units linked by, for example, amide bonds. Theamino acids can be any amino acid, including natural or non-naturalamino acids, and are preferably alpha amino acids. The amino acids canbe identical or different from one another. Examples of suitable aminoacids include amino alkyl-amino acids, such as (2-aminoethyl)-aminoacid.

Bases are attached to the amino acid backbone by molecular linkages.Examples of linkages are methylene carbonyl, ethylene carbonyl and ethyllinkages. The resulting pseudopeptide is known as a peptide nucleic acid(PNA). (Nielsen et al., Peptide Nucleic Acids-Protocols andApplications,Horizon Scientific Press, pages 1-19; Nielsen et al., Science 254:1497-1500.)

An example of a PNA comprises units of N-(2-aminoethyl)-glycine. (SeeFIG. 5.) Further examples of PNAs include cyclohexyl PNA, retro-inverso,phosphone, propionyl and aminoprohne PNA-(Nielsen et al, Peptide NucleicAcids-Protocols and Applications, Horizon Scientific Press, page 7.)

PNAs can be chemically synthesized by methods known in the art, e.g. bymodified Fmoc or tboc peptide synthesis protocols. PNAs have manydesirable properties, including high melting temperatures (Tm), highbase-pairing specificity with nucleic acid molecules and an unchargedbackbone. Additionally, a PNA does not confer RNase H sensitivity on thetarget RNA, and generally has good metabolic stability.

The length of the base-pairing segment is not critical, as long as thelength is sufficient to hybridize specifically to the target nucleicacid. For example, the base-pairing segment can have from about six toabout one hundred bases, more preferably from about eight to about fiftybases, and most preferably from about ten to about twenty bases.

Various factors can be considered when determining the length of thebase-pairing segment, such as target specificity, binding stability,cellular transport and in vivo delivery. For example, a base-pairingsegment should be long enough to stably anneal to a target nucleic acid.Also, the segment should be long enough to allow for target specificitysince, for example, a short sequence has a higher probability ofoccurring elsewhere in the genome vis-a-vis a long sequence. However, abase-pairing segment should not be so long that it binds too tightly tothe target nucleic acid thereby possibly inhibiting late steps ofsplicing, or mRNA transport through the nuclear pore, or cytoplasmictranslation of the mRNA-In addition, an excessively long base-pairingsegment may anneal to secondary targets with partial complementarity. Afurther consideration is that the length of a base-pairing segment mayaffect the efficiency of in vivo delivery.

The nucleic acid molecule to which the base-pairing segment anneals maybe any nucleic acid molecule. For example, the nucleic acid can be anysingle-stranded nucleic acid, including single-stranded RNA and DNA.

In one embodiment, the modulation of gene expression pertains to themodulation of RNA splicing. The base-pairing segment is joined to amoiety that modulates splicing, to form the chimeric molecules of thepresent invention. The modulation can be up-regulation ordown-regulation of splicing. More than one chimeric molecule can be usedto modulate splicing.

The present invention is not limited by any particular mechanism ofsplicing. At the time of filing this application, the mechanism ofsplicing is not fully defmed, and the mechanism followed in one contextis not necessarily followed in another context.

In this embodiment, the nucleic acid to which the base-pairing segmentanneals is a pre-DnRNA transcript. The base-pairing segment of thechimeric molecule anneals to a complementary region on the pre-mnRNAtranscript so that the moiety is brought to a position where it canmodulate splicing of the pre-mRNA transcript. The moiety modulatessplicing by promoting spliceosome assembly in proximity to a targetsplice site. The target splice site is the site on the pre-mRNAtranscript where splicing is to be modulated.

Preferably, the base-pairing segment anneals to the pre-mRNA transcriptat a position where the moiety can modulate the splicing withouthindering binding of essential splicing factors to the 5′ and 3′ splicesites, the branch site, or the exon borders. For example, this positionon the pre-mRNA can be next to the target splice site itself or up to300 residues downstream or upstream from the target splice site,preferably from about two to about fifty residues from the target splicesite, more preferably from about ten to about twenty-five residues fromthe target splice site. The region on the pre-mRNA to which thebase-pairing segment anneals can be an exon or an intron. In some cases,it would be preferable to have the base-pairing segment anneal to anintron since in such a manner the chimeric molecule would never be boundto the spliced mRNA.

The moiety of the chimeric molecule used to modulate pre-mRNA splicingcan be any moiety that modulates pre-mRNA splicing. The moietypreferably comprises a protein domain involved in splicing activation,i.e., a splicing activation domain Such domains are known in the art. Inone example, the protein domain occurs naturally, such as in an SRprotein-SR proteins are proteins that have a domain rich inserine-arginine dipeptides. Examples of naturally-occurring SR proteinsinclude SF2/ASF, SC35, SRp40 and SRp55. Active fragments of thesenaturally-occurring protein domains can also be used as the moiety.Another example of a splicing activation domain comprises a sequencerich in arginine-glutamic acid dipeptides.

The domain involved in splicing activation can also be a syntheticsequence that has been designed to have a function that is similar tothat of the naturally occurring protein domain. An example of asynthetic domain with a function similar to a naturally occurringprotein domain comprises a sequence that is rich in arginine-serinedipeptides. At least one serine can be replaced with a glutamate oraspartate to mimic a constitutively phosphorylated domain. Anotherexample of a synthetic domain, with function similar to that of anatural splicing activation domain, comprises a sequence that is rich inarginine-glutamic acid dipeptides.

Alternatively, the moiety can be synthetic, short polymers withalternating charae. Such polymers are called polyampholytes. (Hampton etal., Macromolecules 33: 7292-7299 (2000); Polymeric MaterialsEncyclopedia, Salamone, Ed., CRC Press (1996).) Preferably, thesepolymers contain monomers with dimensions similar to that of arginineand phosphoserine. Additionally, the spacing between the monomers ispreferably similar to that of the spacing between arginine andphosphoserine.

The length of the domain involved in splicing activation can vary. Forexample the domain can include from about three to about two hundredamino acid residues, more preferably from about five to aboutone-hundred residues, and most preferably from about fifteen to aboutthirty residues.

Analogously, the number of dipeptide repeats in the domain can alsovary. For example, the number of dipeptide repeats can be from about twoto about one hundred repeats, more preferably from about five to aboutfifty repeats, even more preferably from about eight to abouttwenty-five repeats, and most preferably from about ten to about fifteenrepeats.

There are several factors to be considered when determining the lengthof the splicing activation domain. For example, longer domains may bemore potent; however, chimeric molecules produced for therapeuticintervention, in most cases, should be as small as possible.

In another embodiment, the moiety is a protein or a single-stranded or adouble stranded nucleic acid molecule that includes a binding site for asplicing protein. The splicing protein that binds to this moiety ispreferably a splicing protein that is endogenous to an organism, such asa SR protein. In another embodiment the splicing protein can beexogenous, including naturally-occurring and synthetic proteins. Someexamples of splicing proteins are those containing the splicingactivation domains described above.

In a preferred embodiment, the moiety that includes a splicingprotein-binding site is an RNA segment. The end of the RNA segment thatis not joined to the base-pairing segment, optionally, has adjoiningnon-RNA residues. These non-RNA residues protect the RNA fromribonucleases. A few examples of such non-RNA residues include aminoacid residues; modified oligonucleotides, such as 2′-O methyloligonucleotides; morpholino oligos and PNAs.

In another embodiment, the moiety is a modified RNA. The modified RNAcan be any modified RNA that includes a binding site for a splicingprotein. An example of such a modified RNA is 2′-O methyl RNA In anotherembodiment, the moiety is a small molecule that modulates splicing; or asmall molecule that binds specifically to a splicing protein or splicingprotein domain. For example, small molecules that bind specifically to asplicing protein, or splicing domain, can be obtained by screeningchemical, combinatorial, phage display or RNA aptamer libraries. In oneembodiment, the small molecule can be biotin. In this case, a splicingprotein or splicing domain can be fused to avidin or streptavidin.

In one embodiment, the modulation of pre-nRNA splicing pertains toenhancing the inclusion of certain portions of the pre-mRNA transcript,i.e. a target exon, into the spliced mRNA. The use of the chimericmolecules of the present invention to promote exon inclusion has manyapplications.

For example, promotion of exon inclusion can be used to improve orrestore correct RNA splicing for defective genes in which inappropriateexon skipping results from mutations. These mutations include missense,nonsense, synonymous and frameshift mutations; and small intra-exonicdeletions and insertions.

For example, the chimeric molecules of the present invention can promoteexon inclusion where an exonic splicing enhancer (ESE) is absent or hasbeen wholly or partially inactivated by a mutation, or a singlenucleotide polymorphism. ESEs are sequences which are present in eitherconstitutive or alternative exons of certain genes, and are required forthose exons to be spliced efficiently. It is believed that when a normalESE is present, one or more SR proteins bind to the pre-mRNA transcriptvia the proteins' RNA-recognition motif(s). (See FIG. 2.) Each SRprotein recognizes a unique, albeit highly degenerate ESE sequence motifunder splicing conditions. (See FIG. 3.) The arginine-serine-rich domainof the SR protein serves to promote spliceosome assembly at the splicesite(s) flanking an exon thereby enhancing inclusion of theESE-containing exon in the spliced mRNA. If an ESE is absent or has beeninactivated, binding of an SR protein may be precluded; and as a result,exon recognition is impaired.

In order to compensate for the absent or inactive ESE, the base-paringsegment of the chimeric molecules of the present invention are designedso that they anneal to a target sequence on the pre-mRNA transcript bybase-pairing. Once bound, the moiety of the chimeric molecule canpromote spliceosome assembly at a target splice site flanking aparticular exon, thereby promoting the inclusion of the exon.

For example, the defective splicing of a mutant BRCA1 transcript can becorrected by the chimeric molecules of the present invention. An ambernonsense mutation (Glu1694Ter) involving a G to T transversion atposition 6 of exon 18 of the breast cancer susceptibility gene BRCA1causes inappropriate skipping of the entire constitutive exon 18 invivo. (Nazoyer et al., Am. J. Hum. Genet. 62:713-715 (1998).) Thismutation was found in a family with eight cases of breast cancer orovarian cancer. The identical mutation in genomic DNA was also reportedfive times in the 2000 BRCA1 Information Core Database. Skipping of exon18 results in retention of the same reading frame and removal of 26amino acids, disrupting the first BRCT domain of BRCA1.

In one example of the present invention, the chimeric molecule used topromote exon inclusion was a twelve-residue PNA joined to a twenty-tworesidue peptide. (See FIG. 6.) The PNA bases were complementary to asegment of BRCA1 exon 18, just downstream from the mutant site on theexon. The peptide portion of the chimeric molecule in this exampleincluded ten arginine-serine (RS) dipeptide repeats. The chimericmolecule effectively promoted exon 18 inclusion in the spliced mRNA.

Exon skipping can also result from mutations in introns, at or nearsplice sites, or from mutations that activate cryptic splice sites. Thepresent invention includes promotion of ekon inclusion in thesesituations. As stated above, the chimeric molecules can be used topromote spliceosome assembly at a target splice site on the pre-mRNAtranscript.

The base-pairing segment does not have to anneal directly across amutation As stated above, the base-pairing segment is required only toanneal to a position on the pre-mRNA where it can promote spliceosomeassembly at splice sites flanking a target exon. This position is notnecessarily on a mutation.

There may be multiple alleles of a given gene with a certain mutation.Since it is not required that the base-pairing segment anneal directlyacross a mutation, a single chimeric molecule of the present inventioncan be used to correct exon skipping in all of the alleles that causeskipping of a particular exon.

In one embodiment, the chimeric molecules promote inclusion of an exonin a mRNA transcript where the inclusion does not occur naturally, orwhere the inclusion occurs only partially.

For example, splicing of exon 7 of the SMN2 gene can be promoted by thechimeric molecules of the present invention. The SMN2 gene is almostidentical to the SMN1 gene, except that splicing of the SMN2 gene failsto efficiently include exon 7. (See FIG. 1) The SMN2 gene differs onlyin subtle ways from the SMN1 gene, but only the latter is thought to becritical for viability and for proper motor neuron function in normalindividuals.

In individuals with spinal muscular atrophy (SMA), however, both copiesof the SMN1 gene are missing or are grossly defective. The patientssurvive, albeit with SMA disease, because they have one or more copiesof the SMN2 gene. Splicing of the SMN2 pre-mRNA yields mostly mRNA inwhich the penultimate exon (exon 7) is skipped. Messenger RNA whichincludes exon 7 is generated only at low levels.

It has been shown that exon 7 is predominantly skipped in SMN2 pre-mRNAand included in SMN1 pre-mRNA because of the presence of a cytosine atposition +6 of exon 7 in the SMN1 gene versus a thymine at the sameposition in the SMN2 gene. The chimeric molecules of the presentinvention can be targeted so that SMN2 exon 7 is included in the mRNAtranscript. The cytosine and thymine at this position are part ofsynonymous codons, and hence SMN2 mRNA containing exon 7 encodes fullyfunctional survival-of-motor-neuron protein.

In another embodiment, the modulation of pre-mRNA splicing pertains tomodulating alternative splicing. Alternative splicing includes anyvariations in the processing of pre-mRNA that allow more than onepossible protein to be made from a single gene. For example, a pre-mRNAtranscript can be spliced in various ways so that the fmal mRNA canappear in multiple isoforms.

The chimeric molecules of the present invention can promote theformation of a particular isoform vis-á-vis a different isoform. Forexample, the chimeric molecules can be used to enhance a particularalternative splicing pathway vis-á-vis a different splicing pathway. Asdescribed above, the chimeric molecule anneals to a position on thepre-mRNA transcript whereby the molecule can promote formation of aspliceosome assembly in proximity to a target splice site. The chimericmolecules can thus force the inclusion of specific exons in the mRNAtranscript to result in the ectopic expression of particular isoforms.

Through modulation of alternative splicing, the chimeric molecule canalso decrease the expression of a gene, or one or more of its isoforms.For example, one of the alternative exons may contain an in-framenonsense codon, resulting in degradation of the spliced mRNA bynonsense-mediated decay. In another example, a non-functional truncatedpeptide is encoded when an alternative exon is included.

Targeting the chimeric molecule to promote inclusion of such exons woulddownregulate the expression of a particular gene or reduce the activityof the protein encoded. Genes to which such downregulation can betargeted include, for example, an oncogene or viral gene.

The chimeric molecule can also be used to improve gene expression. Forexample, in some cases of gene expression splicing of a particularintron is a rate-limiting step. Unspliced or partially splicedtranscripts usually accumulate in the nucleus and are not accessible tothe protein synthesis machinery. The chimeric molecule can be targetedso as to increase the rate of splicing of the rate-limiting intron fromthe pre-mRNA transcript. In other cases of gene expression, there is anintron that normally remains largely unspliced. The chimeric moleculecan force the splicing of such an intron. In both these cases the use ofthe chimeric molecule can result in an increase of fully spliced mRNAthat is available for transport to the cytoplasm and for translation,thus resulting in increased protein production.

In another application of the invention, the chimeric molecules canpromote pre-mRNA splicing that does not occur naturally, or that occursonly partially. As described above, a chimeric molecule is targeted toany position on the pre-mRNA transcript where promotion of spliceosomeassembly is desired.

For example, splicing can be forced in a virus or a retrovirus. Inparticular, viruses, such as the HIV retrovirus, have evolved signalsand mechanisms to allow transport of unspliced or partially splicedmRNAs in addition to fully spliced mRNAs. The viral life cycle requiresproteins encoded by all of these RNAs. Thus, increasing the removal ofsome or all of the viral introns by splicing (oversplicing) would bedetrimental to the virus. The chimeric molecules can be targeted to oneor more viral exons to promote such splicing.

In one embodiment, the modulation of pre-mRNA splicing pertains tocorrecting defective splicing. Defective splicing is splicing of apre-mRNA transcript that results in a defective protein product.Typically, the splicing of the transcript is defective due to smalldefects, i.e. mutations, in the genetic material which are carriedforward to the pre-mRNA transcript. The defective splicing can result information of a spliced mRNA transcript which contains an exon which islarger or smaller than the corresponding normal exon; formation of acompletely new exon not found in the normal transcript; elimination ofan exon needed to express a normal protein product; or a fusion of anexon of one gene with the exon of another gene. These defects result indefective protein products.

In another embodiment, the modulation of gene expression is themodulation of translation. The modulation can be up-regulation ordown-regulation of translation. The base-pairing segment is joined to amoiety that modulates translation, to form the chimeric molecules. Thenucleic acid molecule to which the base-pairing segment anneals is anmRNA transcript. More than one chimeric molecule can be used to modulatetranslation. The present invention is not limited by any particularmechanism of translation. Preferably, PNA-peptides can be used to annealto the mRNA.

More specifically, the base-pairing segment of the chimeric moleculeanneals to a complementary region on the mRNA transcript so that themoiety is brought to a position where it can modulate translation of themRNA transcript. Translation requires the presence of various factors,co-factors and building blocks, besides the mRNA template, includingribosomes; amino-acylated tRNAs; initiation, elongation and releaseprotein factors; GTP; ATP; etc. The moiety of the chimeric moleculerecruits one or more of these components to the mRNA to be translated.

The moiety can include, for example, a peptide sequence of the rotavirusnonstructural protein NSP3. In particular, the peptide sequence can be(MYSLQNVISQQQSQIADLQNYCNKLEVDLQNKISSLVSSVEWYLKSMELPDEIKTDIEQQLNSIDVINPINAIDDFESLIRNIlLDYDRILMFKGLMRQCNYEYTYE) (SEQ. ID.NO.:1). (Piron et al., Journal of Virology 73:5411-5421 (1999); Vende etal., Journal of Virology 74:7064-7071 (2000).) The action of thispeptide sequence includes the recruitment of eukaryotic initiationfactor 4GI (eIF4GI).

Alternatively, the moiety can include the N-terminal domain of theinfluenza virus NSl protein, in particular the first one hundredthirteen amino acids of the N-terminal domain. (Aragon et al., MCB, 20:6259-6268 (2000).) The action of this domain also includes therecruitment of eukaryotic initiation factor 4GI (eIF4G]).

Alternatively, the moiety can include domains of poly(A)-binding protein(PAB). In particular, the RNA-recognition motif (RRM) domains 1 and 2,i.e., amino acids 1-182 of the PAB protein. A binding site for eIF-4Glies in RRMs 1 and 2. EIF-4G forms part of a cap-binding complex witheIF-4E. (Gray et al., EMBO, 19: 4723-4733 (2000).)

In another embodiment, the modulation of gene expression is themodulation of transcription. The base-pairing segment is joined to amoiety that modulates transcription to form the chimeric molecules. Themoiety can be a peptide which comprises up to about one hundred aminoacid residues. Modulation can be up-regulation or down-regulation oftranscription. More than one chimeric molecule can be used to modulatetranscription.

The target nucleic acid to which the base-pairing segment anneals is adouble-stranded nucleic acid molecule. The nucleic acid can be anydouble-stranded nucleic acid molecule, including double-stranded DNA,double-stranded RNA and mixed duplexes between DNA and RNA.

Preferably, the chimeric molecules are targeted to double-stranded DNA.Any position on the DNA that allows the moiety to recruit varioustranscription factors to, for example, promoter or enhancer elements onthe DNA may be targeted. The chimeric molecules bind to thedouble-stranded DNA in any manner in which the chimeric molecules canbase-pair to the double-stranded DNA.

For example, a base-paring segment can bind to double-stranded DNA bystrand displacement. The base-pairing segment can bind to DNA in eithera parallel or an anti-parallel orientation.

In one embodiment, a strand displacement complex is formed by a chimericmolecule that has a homopyrimidine base-pairing segment and a secondmolecule. A homopyrimidine base-pairing segment has several pyrimidinesin a row. For example, the homopyrimidine base-pairing segment can havefive to twenty pyrimidines in a row, more preferably ten to fifteenpyrimidines in a row. The second molecule can be a PNA, modified oligoor another chimeric molecule. The base-pairing segment of the chimericmolecule binds by Watson-Crick base-pairing to a target segment of a DNAstrand. The second molecule forms Hoogsteen hydrogen bonds with the sameDNA strand. Thus, a clamp is formed with two molecules binding one DNAstrand. The DNA stretch complementary to the target DNA is displaced andremains single stranded. The resultant complex is termed, a “triplexinvasion.”

Preferably, the base-pairing segment is a PNA. Accordingly, the “triplexinvasion” can be represented as PNA•DNA-PNA/DNA, where “•” representsHoogsteen hydrogen bonds and “-” represents Watson-Crick base-pairing.In one embodiment, two PNA strands may be covalently connected by aflexible linker and are thus termed bis-PNA.

Alternatively, a strand displacement complex can be formed by a chimericmolecule comprising a homopurine base-pairing segment. A homopurinebase-pairing segment has several purines in a row. For example, thehomopurine can have five to twenty purines in a row, more preferably tento fifteen purines in a row. The base-pairing segment of a singlechimeric molecule binds the target DNA via Watson-Crick base-pairing.The DNA stretch complementary to the target DNA is displaced and remainssingle stranded. The resultant complex is termed, a “duplex invasion.”

Preferably, the base-pairing segment is a PNA. Accordingly, the “duplexinvasion” can be represented as PNA-DNA/DNA, where “-” representsWatson-Crick base-pairing.

Alternatively, a strand displacement complex can be formed by a chimericmolecule and a second molecule, both of which comprisepseudo-complementary base-pairing segments. The base-pairing segmentsare termed pseudo-complementary because adenine and thymine bases arereplaced with diamrinopurine and thiouracil bases, respectively. Theformation of base-pairing segment duplexes is prevented by thediaminopurine and thiouracil bases. The second molecule can be a PNA,modified oligo or another chimeric molecule.

These base-pairing segments achieve strand displacement by the formationof two duplexes via Watson-Crick base-pairing. The resultant complex istermed “double-duplex invasion.”

Preferably, the base-pairing segment is a PNA. Accordingly the“double-duplex invasion” can be represented as PNA-DNA/PNA-DNA where “-”represents Watson-Crick base-pairing.

The moiety that modulates transcription can be any transcriptionactivation domain. The length of this domain is preferably the minimumlength that has the desired activity. Multiple domains provide increasedactivity. For example, such a domain can have up to one hundredresidues, preferably up to fifty residues and most preferably up tothirty residues. An example of such a domain is AH(PEFPGIELQELQELQALLQQ) (SEQ. ID. NO.:2). (Giniger et al., Nature(London) 330, 670-2 (1987.) Another example is human oct-2glutamine-rich peptide, Q18III. This domain is eighteen amino acidslong. Preferably, three tandem copies are used to give strong activityin a protein context. (Tanaka and Herr, Mol Cell Biol 14: 6056-67(1994).) Another example of a transcription activation domain isNF-kappa B RelA (p65) subunit acidic activation module. This domain iseleven amino acids long. Preferably, two tandem copies are used to givestrong activity. (Blair et al, Mol Cell Biol 14: 7226-34 (1994).) Otherexamples are homopolymeric activation modules. These activation modulescontain ten to thirty glutamines, or about ten prolines. (Gerber et alScience 263: 808-811 (1994).) Another example is a VP16 activationdomain derived peptide. This domain comprises eleven amino acids(DALDDFDLDML). (SEQ. ID. NO.:3). Other peptides derived from thisnatural sequence can be used which are fifteen to twenty amino acids inlength and have specific arrays of aspartate and leucine residues.(Seipel et al, Biol. Chem. Hoppe Seyler 375: 463-70 (1994).)

To achieve modulation of gene expression, a gene expression system iscontacted with the chimeric molecules. The gene expression system refersto any system in which genes may be expressed. The gene expressionsystem may be in vitro, ex vivo or in vivo. In vitro systems typicallyinclude cultured samples and cell-free systems. Ex vivo systemstypically include cells or organs removed from a living animal. In vivosystems include living animals. Thus, the gene expression systemincludes, but is not limited to, any cell, tissue, organ, whole organismor in vitro system that expresses the gene while in contact with thechimeric molecules.

The chimeric molecules can be modified to optimize their use for variousapplications. In particular, these methods include modifications toimprove delivery, cellular uptake, intracellular localization,pharmacokinetics, etc.

One manner in which the chimeric molecules can be modified is by theaddition of specific signal sequences. The signal sequences may beincorporated into the chimeric molecules at any point during synthesis.

For example, nuclear retention signals (NRS) can be incorporated intothe chimeric molecules. In particular, the effectiveness of the chimericmolecules in modulating pre-mRNA splicing can be improved if, once themolecules are imported to the nucleus, they are efficiently retainedthere. Nuclear retention-can preclude, for example, the possibility oftoxicity due to unwanted inhibition of cytoplasmic translation of maturemRNA However, the off rates of chimeric molecules bound to the mRNAtranscript need to be considered. For example, the stable hybridizationof chimeric molecules targeted to exon 7 of the SMN pre-mRNA transcriptcoupled with dominant retention signals, may preclude mRNA export, andhence preclude the synthesis of SMN protein. (In this case, it ispreferred that the chimeric molecules target the intronic regions of theSMN pre-mRNA transcript so that the chimeric molecules would notassociate with the mature mRNA.) Examples of NRSs include the hnRNP Cnuclear retention signal (Nakielny et al., J. Cell Biol. 134(6):1365-73(1996).)

Additionally, signal sequences which enhance transport across cellmembranes may be incorporated, such as polylysine, poly(F-K), andnuclear localization signals.

Also signal sequences that promote transport across the brain-bloodbarrier (BBB) can be incorporated. Transport across the BBB can beeither by diffusion or by saturable receptor systems. Examples ofsignals that would promote transport across the BBB is the Dowdy Tatpeptide, and peptide sequences that are part of MIF-1, leptin,interleukin-1, and epidermal growth factor. (Kastin et al., Brain Res.848 (1-2):96-100 (1999).)

Also signal sequences that promote transport across the placentalbarrier can be incorporated. (Chandorkar et al., Adv. Drug Deliv. Rev.14;38(1):59-67 (1999); Simister et al., Eur. J. Imnunol. 26(7):1527-31(1996).)

Additionally, signal sequences can be included if it is desired totarget the chimeric molecule to different cell types or different partsof a cell. In an example of an in vivo application of this invention,the chimeric molecules are administered to SMA patients. In this case,the chimeric molecule can include a small peptide ligand that isspecific for a neuromuscular junction receptor.

Additionally, cellular uptake can be enhanced by the addition of aprotein transduction domain on either side of the moiety. Thetransduction domain can be an amphipathic helix with multiple basicamino acids that may interact with the anionic face of the plasmamembrane. Preferred protein transduction domains include residuesderived from the N-terminus of MV-TAT protein (e.g., YARAAARQARA (SEQ IDNO:4) and YGRKKRRQRRR (SEQ ID NO.: 5)). Additionally, peptides derivedfrom Drosophila Antennapedia are also effective. All these domainsfacilitate bi-directional passage across the plasma membrane ofrelatively large or very large molecules that are normally notinternalized. A preferred chimeric molecule, which modulates splicing,is a PNA-peptide with the shortest arginine-serine domain determined tobe active with the TAT peptide juxtaposed to either the N-terminal orC-terminal end of the domain.

Additionally, transport across cell membranes can be enhanced bycombining the chimeric molecule with a carrier. Some examples ofsuitable carriers include cholesterol and cholesterol derivatives;liposomes; protamine; lipid anchored polyethylene glycol; phosphatides,such as dioleoxyphosphatidylethanolamine, phosphatidyl choline,phosphatidylglycerol; α-tocopherol; cyclosporin; etc. In many cases, thechimeric molecules can be mixed with the carrier to form a dispersedcomposition and used as the dispersed composition.

The chimeric molecule can be administered to mammals in any manner thatwill allow the chimeric molecules to modulate gene expression. Mammalsinclude, for example, humans; pet animals, such as dogs and cats;laboratory animals, such as rats and mice; and farm animals, such ashorses and cows. Additionally, mammals, for the purposes of thisapplication, include embryos, fetuses, infants, children and adults.Examples of the administration of the chimeric molecules include variousspecific or systemic administrations, e.g., injections of the chimericmolecules.

For example, the appropriate chimeric molecules can be delivered to SMApatients in any manner that allows for enhancement of the incorporationof exon 7 of the SMN2 gene. The chimeric molecules are preferablydelivered inz utero or at an appropriate time after birth. In the mousemodel, an appropriate time is forty-eight hours after birth. Anappropriate time after birth for humans is the time that corresponds toforty-eight hours in the mouse model. The administration of the chimericmolecules at a significant time after birth can prevent furtherdegeneration of motor neurons and/or partially reverse the course of adisease after its onset. A significant time after birth can be up to theappearance of motor neuron degenerative symptoms, or after the onset ofthe disease. Also the chimeric molecules can be administered throughoutthe lifetime of a patient.

The present invention provides a method of making the chimericmolecules. The chimeric molecules are formed by joining the base-pairingsegment and the moiety. The base-pairing segment can be joined to themoiety in any manner that will allow the base-pairing segment to becovalently bound to the moiety.

For example, a peptide moiety and a base-pairing segment can beseparately synthesized and then chemically conjugated to one another.Several peptide moieties can be conjugated to a single base-pairingsegment. Alternatively, several base-pairing segments can be conjugatedto a single moiety.

The structure of a PNA-peptide conjugate to be used in the presentinvention can be C-peptide-N-5′-PNA-3′; C-peptide-N-3′-PNA-5′;N-peptide-C-5′-PNA-3′; N-peptide-C-3′-PNA-5′; 5′-PNA-3′-C-peptide-N;5′-PNA-3′-N-peptide-C; 3′-PNA-5′-C-peptide-N or 3′-PNA-5′-N-peptide-C.

A PNA may be conjugated to a peptide by methods known in the art. See,for example, Tung et al., Bioconjug. Chem. 2:464-5; Bongartz et al.Nucleic Acid Res. 22: 4681-8; Reed et al., Bioconjuig. Chem. 6:101-108;and de La Torre et al. Biocoijug. Chem. 10:1005-1012.

In a preferred embodiment, a PNA and a peptide moiety can beincorporated sequentially during synthesis in a single automatedmachine, thereby obviating post-synthesis conjugation steps. The singleautomated machine can be a peptide synthesizer or certain modifiedoligonucleotide synthesizers. Either the moiety or the PNA can besynthesized first. Peptides are synthesized from C-to N-terminus, andPNA from 3′ to 5′. Thus, chimeric molecules can be made in a single stepas N-peptide-C-5′-PNA-3′ or 5′-PNA-3′ -N-peptide-C.

The chimeric molecule can optionally include a spacer sequence betweenthe base-pairing segment and the moiety. The spacer sequenceadvantageously provides conformational flexibility to the molecule. Thespacer can include any series of atoms or molecules.

For example, the units of the spacer sequence can be made of amino acidresidues. The residues in the spacer are either the same or anycombination of amino acid residues. Preferably, the residues have aninert character. In a preferred embodiment the amino acid residues areone or more glycine residues.

Additionally, the units of the spacer can be made of inert alkyl groups,e.g., methylene groups.

In another embodiment, one or more hydrophilic linkers can be introducedinto the spacer during chemical synthesis. An example of a hydrophiliclinker monomer is amino-3,6-dioxaoctanoic acid.

The length of the spacer sequence can vary. The spacer typicallyincludes from about one to about one hundred units; more preferably fromabout two to about fifty units; most preferably from about five to aboutfifty units.

A PNA has the advantage that it can be coupled to a peptide moiety viaautomated synthesis. Other base-pairing segments can be covalentlyjoined by a chemical conjugation reaction. To facilitate the joining ofthe base-pairing segment and the moiety, the base-pairing segment caninclude a nucleotide with a reactive functional group. The reactivefunctional group can be any functional group that facilitates coupling.Examples of reactive functional groups include reactive amino,sulffhydryl and carboxyl groups. An example of a reactive amino group isN-hexylanmino.

For example, a derivatized nucleotide with an alkyl amino, e.g. anN-hexylamino group, can be incorporated into the base-pairing segment.In this embodiment, the peptide moiety includes, for example, anN-terminal cysteine.

Additionally, or alternatively, reactive groups can be included on thepeptide moiety.

Alternatively, the base-pairing segment and the peptide moiety can bejoined by means of a bifunctional crosslinker. The bifunctionalcrosslinker can be a heterobifunctional crosslinker, such asN-[γ-maleimidobutyryloxy]sulfosuccinimide ester. This crosslinkerprovides a 6.8 Å spacer (J. Immunol. Methods, 1988 August 9;112(1):77-83). Additionally, homo-bifunctional crosslinkers can be used.

In one embodiment the chimeric molecule has a linear structure. Inanother embodiment the chimeric molecule has a branched structure. In abranched structure, the moiety is attached to an internal residue of thebase-pairing segment; or the base-pairing segment is attached to aninternal residue of the moiety.

The invention also relates to methods for modulating expression of anucleic acid molecule. The methods comprise contacting an appropriatenucleic acid molecule with any of the chimeric molecules describedabove. The chimeric molecules bind to the nucleic acid molecule at anylocation that allows the moiety to modulate expression.

In one example, the invention relates to a method for modulatingsplicing and/or translation. The method comprises contacting asingle-stranded nucleic acid molecule with any of the chimeric moleculesdescribed above that comprises: a) a base-pairing segment thatspecifically binds to a portion of a single-stranded nucleic acidmolecule; and b) a moiety that modulates splicing and translation. Thebinding of the base-pairing segment allows the moiety to modulate saidsplicing and translation. The single-stranded nucleic acid molecule may,for example, be a pre-mRNA transcript.

The chimeric molecule binds to the single-stranded nucleic acidmolecule, e.g., a pre-mRNA transcript, at any location that allows themoiety to modulate splicing and translation. For example, the chimericmolecule binds to the single-stranded nucleic acid molecule at about 0to about 300 residues from a splice site on the nucleic acid molecule.The binding may, for example, occur in either an intron or an exon.

The method may, for example, result in modulation of the rate ofsplicing, or in modulation of alternative splicing. Modulation ofalternative splicing may, for example, result in an increase or in adecrease of the expression of a gene. Decreasing the expression of agene is advantageous, for example, in the case of an oncogene or a viralgene. Alternatively, modulation of splicing promotes inclusion of atarget exon in a mRNA transcript. Such inclusion is desirable when, forexample, an exon fails to be spliced because an exonic splicing enhancerof the exon is absent or inactive. The exonic splicing enhancer may, forexample, be absent or inactive due to a nonsense mutation, missensemutation, synonymous mutation, frameshift mutation, intra-exonicdeletion, intra-exonic insertion or single-nucleotide polymorphism.

The target exon may, for example, be an exon of the SMN2 gene, such asexon 7 of the SMN2 gene. Delivery of exon 7 of the SMN2 gene isimportant, for example, in the case of patients with spinal muscularatrophy. Exon 7 may, for example, be introduced into a gene either inutero or ex utero.

In a preferred embodiment of the method described above, the inventionrelates to a method to correct defective splicing of a pre-mRNAtranscript during pre-mRNA splicing. The method comprises contacting thepre-mRNA transcript with any of the chimeric molecules described abovethat comprise: a) a base-pairing segment that specifically binds to thepre-mRNA transcript; and b) a moiety that modulates splicing. Thebinding of the base-pairing segment allows the moiety to correctdefective splicing.

In another embodiment, the invention relates to a method for modulatingtranscription. The method comprises contacting a double-stranded nucleicacid molecule with any of the chimeric molecules described above thatcomprise: a) a base-pairing segment that specifically binds to a portionof the double-stranded nucleic acid molecule; and b) a moiety thatmodulates transcription. The chimeric molecules bind to thedouble-stranded nucleic acid molecule at any location that allows thepeptide to modulate transcription. The moiety is preferably a peptidewhich comprises from about two to about one hundred amino acid residues.

In a final embodiment, the invention relates to a method of making anyof the chimeric molecules described above. The method comprisescovalently bonding a base-pairing segment that binds specifically to anucleic acid molecule, and a moiety that modulates gene expression

EXAMPLES

The following examples are intended to show the practice of theinvention and are not intended to restrict the scope of the presentinvention.

Example 1 SR Protein Motifs

A functional SELEX strategy coupled with the S100 complementation assaywas developed to define the role of SR proteins in constitutivesplicing. By means of this strategy sequence motifs that act asfunctional enhancers in the presence of the cognate recombinant SRprotein were defined. FIG. 3 shows the motifs that were found for fourSR proteins, displaying each nucleotide with a size proportional to itsfrequency at that position of the consensus. Each consensus was derivedfrom an alignment of -˜30 functional sequences selected by splicing inthe presence of a single SR protein-The. motifs are highly degenerate,probably reflecting evolutionary constraints on the presence of exonicsplicing signals within a vast set of unrelated protein-coding segments.The degeneracy is also consistent with the RNA-binding properties of SRproteins, which exhibit significant sequence preferences, butnevertheless can bind reasonably tightly to very diverse RNA sequences.Thus, a relatively small number of SR proteins can mediate enhancementvia elements present in an extremely diverse set of exons. Additionaldiversity and specificity are probably achieved through other factorsthat act as activators or co-activators of SR proteins, such asSRm160/300 or the Tra2 proteins.

Statistical methods were used to evaluate the occurrence of the enhancermotifs, identified by SELEX in natural sequences. Usingnucleotide-frequency scoring matrices, the motifs for four SR proteins(SF2/ASF, SC3 5, SRp40 and SRp55) were found to be more prevalent inexons than in introns, and tend to cluster in exonic regionscorresponding to known natural enhancers. Each type of motif appears tobe necessary for enhancement when the cognate SR protein is the sole onepresent in the S100 complementation assay. However, the presence of amotif is not sufficient for activity, as context can be extremelyimportant.

Example 2 Mechanism of Exon Skipping in the BRCA1 gene

The recently derived SF2/ASF, SC35, SRp40, and SRp55 motif-scoringmatrices were used to analyze the wild-type and a particular familialmutation in exon 18 of BRCA1. Multiple high-score motifs for each typeof ESE are distributed throughout this exon (FIG. 13). The mutation atposition 6 specifically disrupts the first of three high-score SF2/ASFmotifs. To study the mechanism of exon skipping, wild-type and mutantminigenes were constructed. These minigenes include exons 17 through 19and shortened versions of introns 17 and 18.

Radiolabeled transcripts from these minigenes were spliced in vitro(FIG. 14). The two pre-mRNAs were spliced in strikingly different ways:with wild-type pre-mRNA (WT), exon 18 was efficiently included (lane 1),whereas with mutant pre-mRNA (NT), exon 18 was predominantly skipped(lane 2). FIG. 4 shows the time course results of the in vitro splicingassay.

Although the extent of exon inclusion and skipping varied with differentextract preparations or buffer conditions, the ratio of exon skippingover inclusion was reproducibly greater with the mutant pre-mRNA. Theoverall recovery of labeled RNA was not significantly affected by themutation Rig. 14), making differential mRNA stability an unlikelyexplanation for the different splicing patterns observed. This result isconsistent with the SF2/ASF high-score motif distribution, stronglysuggesting that the nonsense mutation disrupted an ESE.

There is no a priori reason why ESE inactivation should resultpreferentially from in-frame nonsense mutations, as opposed to othertypes of base substitution. To examine the requirement for a nonsensemutation, two additional BRCA1 minigene transcripts were designed (FIG.15 a). One of the mutant pre-mRNAs, ML, has a G to A transition at thesame position as the original mutation, and is a missense mutation thatalso eliminates the high-score SF2/ASF motif. The other mutant pre-mRNA,NH, has an amber nonsense mutation in the following codon, but maintainsa high-score SF2/ASF motif. Splicing of the wild-type and the threemutant transcripts was compared in vitro, and quantitation of therelative extent of exon 18 inclusion is shown (FIG. 15 b). Splicing ofthe amber mutant pre-mRNA with a high-score SF2/ASF motif (NH) waspredominantly via exon 18 inclusion, whereas that of the missense mutantwith a disrupted SF2/ASF motif (ML) was primarily via exon 18 skipping.Therefore, exon inclusion strongly correlates with a high-score SF2/ASFmotif, and an in-frame nonsense mutation is neither necessary norsufficient for exon skipping.

To determine whether the findings with BRCA1 have general significance,it was examined whether point mutations in other genes can also disruptESEs. A database of 50 single-base substitutions known to cause exonskipping in vivo was analyzed. The wild-type and mutant sequences ofeach gene were compared using the above-mentioned motif-scoring matricesfor four SR proteins and their respective threshold values. Remarkably,the search results indicated that more than half of these single-basesubstitutions reduced or eliminated at least one high-score motif forone or more of these SR proteins (Table 1). Over twice as manyhigh-score motifs were reduced or eliminated by the mutations as wereincreased or created by them (43 vs. 21). This excess of high-scoremotifs in the wild-type set of sequences, compared to the mutant set, isstatistically significant (p<0.01, binomial exact test). Therefore, theaberrant exon skipping resulting from missense, nonsense, ortranslationally silent single-base substitutions is frequently, if notalways, due to disruption of a critical ESE. Similar effects can beexpected from small insertions or deletions within exons.

Example 3 Methods for Examples 1 and 2

BRCA1 DNA templates. A portion of the wild-type human BRCA1 gene wasamplified by PCR from human genomic DNA (Promega) using primers T7P1(5′-TAATACGACTCAC-TATAGGGAGATGCTCGTGTACAAGTTTGC) (SEQ ID NO.: 6.) and P6(5′-AAGTACT-TACCTCATTCAGC) (SEQ ID NO.: 7.). The amplified DNA was thenused as a template for three separate PCR amplifications to synthesizeintron-truncated DNA fragments: the first PCR amplified exon 17 and the5′ part of intron 17 using primers T7P 1 and P2(5′-TAAGAAGCTAAAGAGCCTCACTCATGTGGTTTTATGCAGC) (SEQ ID NO.: 8); thesecond PCR amplified the 3′ part of intron 17, exon 18, and the 5′ partof intron 18 using primer P3 (5′-TGAGGCTCTTTAGCTTCTTA) (SEQ ID NO.: 9.)and P4 (5′-AGATAGAGAGGTCAGCGATTTGCA-ATTCTGAGGTGTTAAA) (SEQ ID NO.: 10.);the third PCR amplified the 3′ part of intron 18 and exon 19 usingprimers P5 (5′-AATCGCTGACCTCTCTATCT) (SEQ ID NO.: 1) and P6. The threePCR products were then combined and amplified with primers T7P1 and P6.This overlap-extension PCR generated a BRCA1 minigene (WT) withshortened introns but with otherwise natural intronic splicing signals,wild-type exons 17, 18, and 19, and a T7 bacteriophage promoter. Themutant BRCA1 minigene NL was constructed by overlap-extension PCR withprimers T7P 1 and P6 using as the template the products of two combinedPCR amplifications of WT DNA: the first PCR was done with primers T7P 1and Pna (5′-CACACACAAACTAAGCATCTGC) (SEQ ID NO.: 12); the second PCR wasdone with primers Pns (5′-GCAGATGCTTAGTTTGTGTGTG) (SEQ ID NO.: 13.) andP6. The mutant BRCA1 minigenes ML and NH were constructed similarly,except that the primers Pna and Pns were replaced by primers Pla(5′-CACACACAAACTTAGCATC-TGC) (SEQ ID NO.: 14.) and Pls(5′-GCAGATGCTAAGTTTGTGTGTG) (SEQ ID NO.: 15.), or primers Pha(5′-CACACACCT-ACTCAGCATCTGC) (SEQ ID NO.: 16.) and Phs(5′-GCAGATGCTGAGTAGGTGTGTG) (SEQ ID NO.: 17), respectively.

In vitro transcription and splicing. T7 runoff transcripts wereuniformly labeled with ³²P-GTP or UTP, purified by denaturing PAGE, andspliced in HeLa cell nuclear extracts as described. Briefly, 20 finol of³²P-labeled, m⁷G(5′)ppp(5′)G-capped T7 transcripts were incubated in25-μl splicing reactions containing 5 μl of nuclear extract in buffer D,and 4.8 mM MgCl₂. After incubation at 30° C for 1 hr, the RNA wasextracted and analyzed on 12% denaturing polyacrylamide gels, followedby autoradiography.

Example 4 High-score Motif Analysis

Wild-type or mutant exon sequences from the BRCA1 gene and from thegenes in Table 1 were analyzed with SR protein score matricesessentially as described in Liu et al., Nature Genet. 27:55-58 (2001),except for the use of slightly revised nucleotide frequency matrices andthreshold values. The highest score for each SR protein was calculatedfor each sequence in a random-sequence pool, and the median of thesehigh scores was set as the threshold value for that SR protein. Thethreshold values were: SF2/ASF heptamer motif-1.956; SRp40 heptamermotif-2.670; SRp55 hexamer motif-2.676; SC35 octamer motif-2.383.

FIG. 13 shows the high-score SR protein motifs in BRCA1 exon 18. The78-nt sequence of wild-type exon 18 was searched with fournucleotide-frequency matrices derived from pools of functional enhancersequences selected in vitro (Liu et al., Genes Dev. 12:1998-2012 (1998);(Liu et al., Mol. Cell Biol. 20:1063-1071 (2000).) The thresholds andmaximal values are different for each SR protein. The G at position 6(wild-type) is highlighted. The nonsense mutation that changes this G toa T only affects the first SF2/ASF motif, reducing the score from 2.143to 0.079 (below the threshold).

FIG. 14 illustrates that the in vitro splicing of BRCA1 minigenetranscripts reproduces the exon-skipping phenotype of a nonsensemutation. Wild-type and mutant BRCA1 minigene transcripts were generatedby PCR and ini vitro transcription. An internal portion of eachintron—away from the splice sites and branch site—was deleted togenerate pre-mRNAs of adequate length for in vitro splicing. Wild-type(wt lane 1) and nonsense mutant with low SF2/ASF score (NL, lane 2)radiolabeled transcripts were spliced in HeLa cell nuclear extract, andthe products of the reaction were analyzed by denaturing PAGE andautoradiography.

FIG. 15 illustrates that exon skipping correlates with the SF2/ASFenhancer motif score and not with reading frame disruption.

Example 5 PNA-peptide Targeted Against BRCA1 Exon 18

FIG. 6 shows a PNA-peptide targeted against BRCA1 exon 18. The PNA ispositioned one nucleotide downstream of the mutation at exonic position+6 in BRCA1 exon 18, so it can hybridize equivalently to wild-type andmutant sequences, the former one being used as a control. A 12-residuePNA length was used based on Tm, specificity, PNA sequence-compositionempirical rules having to do with solubility, and cost considerations. Atwenty amino acid peptide (RS)₁₀ was used as the peptide RS domain. TheN-terminus of the peptide was linked to the C/3′ end of the PNA-Twoglycines were included as a linker between the PNA and the RS domain.The PNA-peptide was purified by HPLC and characterized by massspectrometry. As controls, separate RS domain peptide and PNA moleculeswere obtained, as well as a PNA of unrelated sequence.

In vitro splicing experiments, under the conditions described above forthe wild-type and mutant BRCA1 exon 18 inclusion, were carried out inthe presence of the PNA-peptide or the controls. (See FIG. 7.) Theproducts of splicing were analyzed by denaturing PAGE andautoradiography (top). The percentage of exon 7 inclusion wasquantitated (bottom); the points on the curves are open symbols for themutant, and solid symbols for the wild-type. Remarkably, thedose-response curves for each compound show that the PNA-peptide (BRPNA•RS) was effective at promoting exon 18 inclusion with the pre-mRNAharboring the patient nonsense mutation at position +6 (NL mut). Thepeptide alone (RS10 pep) had a slight inhibitory effect, whereas the PNAalone (BR1 PNA) had a slight stimulatory effect that wassequence-specific, since the control PNA of unrelated sequence (TAT1PNA)had no effect. The slight but detectable positive effect of the PNAalone may reflect structural alterations of the pre-mRNA near the exon18 3′ splice site, which somehow facilitate binding of splicingcomponents at the 3′ splice site. In a separate experiment,dose-response curves with BR PNA•RS were carried out at differentmagnesium concentrations. (See FIG. 8.) The C lanes show the inputpre-mRNAs. At both magnesium concentrations, the PNA-peptide targeted toBRCA1 increased the extent of inclusion of the mutant exon 18 in adose-dependent manner.

Example 6 Disruption of an SF2/ASF-dependent Exonic Splicing EnhancerMotif in SMN2 Exon 7

SR Protein ESE Motifs in SMN1 and SMN2 Exon 7.

SMN1 exon 7 was analyzed using four sequence-motif matrices that predictfunctional ESEs recognized by the SR proteins SF2/ASF, SC35, SRp4O andSRp55. Only three motifs with scores above the thresholds for theseproteins are present in SMN1 exon 7: two for SF2/ASF and one for SC35(FIG. 9). Both the SC35 octamer and the SF2/ASF heptamer motifs (FIG.9), which overlap at the 5′ end of SMN1 exon 7, are disrupted in SMN2 bythe C6T substitution (FIGS. 9 and 10).

To uncouple the effect of disrupting both the SF2/ASF and SC3 5high-score motifs, the effect of substituting nucleotides G or A atposition +6 of exon 7 (C6G and C6A) was first calculated. C6G reduces,but does not eliminate, the high scores of both SF2/ASF (3.76 to 2.18)and SC35 (3.87 to 2.95) motifs; C6A likewise results in a reduction inthe SC35 high-score motif (3.87 to 2.59) but has a more severe effect onthe SF2/ASF high-score motif, which drops below the threshold (3.76 to1.26) (FIG. 10). Using a semi-quantitative transient transfection assay,it was confirmed that C6G has essentially no effect on exon 7 inclusion,whereas C6A shows an intermediate phenotype (FIG. 11, lanes 1, 3, 5, 7).Therefore, a strong correlation exists between the SR protein motifscores and exon 7 skipping. Skipping becomes significant in the absenceof an SF2/ASF, but not an SC3 5, high-score motif, showing that theputative ESE is SF2/ASF-specific.

A Second-site Suppressor Mutation that Reconstitutes a High-scoreSF2/ASF Motif at the Original Position in SMN2 Exon 7 Fully RestoresExon Inclusion.

If the motif-score matrices have predictive value, it should be possibleto reconstruct a functional ESE within SMN2 (equivalent to SMN1 C6T) byintroducing a second-site suppressor mutation that recreates ahigh-score motif at the same position, regardless of the precisesequence. To this end, a single A to G transition at position +11 ofexon 7 (A11G) was introduced. This substitution places a highlyconserved G at the sixth position of the SF2/ASF heptamer, replacing thenon-consensus A (FIG. 10, top). Because the SC35 high-score octamerspans positions 1 through 8 of the exon, it is unaffected by this change(FIG. 10). The calculated motif scores for the A11G substitution, inconjunction with each of the four nucleotides at position 6, are shownin FIG. 10. Notably, high-score SF2/ASF heptamers are recreated by theA11G substitution in both the C6T (SMN2) and C6A contexts (C6T/A11G andC6A/A11G, respectively). Accordingly, exon 7 inclusion was fullyrestored in the transient transfection assay only in the presence of anSF2/ASF high-score motif (FIG. 11, lanes 2, 4, 6, 8). The fact that exon7 was fully included even in the absence of an SC35 high-score motif(FIG. 11, lane 4), and that an SC3 5 high-score motif was not sufficientto prevent exon skipping (FIG. 11, lane 5), shows that SC35 does notplay an essential role in mediating exon 7 inclusion.

An SF2/ASF-dependent Heptamer ESE is Necessary and Sufficient to PromoteExon Inclusion in vitro.

To determine whether the SF2/ASF heptamer is a genuine enhancer, it wastested in a heterologous context, namely, exon 18 of BRCA1 pre-mRNAInclusion of this exon in BRCA1 ImRNA depends on the integrity of anSF2/ASF-dependent ESE at positions +4 to +10 of the exon, such that onlymutations that disrupt the ESE cause exon skipping, regardless of themutation type. The SF2/ASF high-score motif in BRCA1 exon 18 wassubstituted with the heptamer from SMN1 exon 7, or with thecorresponding sequence in SMN2 (FIG. 16 a). Remarkably, the SMN1heptamer promoted exon 18 inclusion i7l vitro at levels comparable towild-type BRCA1 (FIG. 16 b, lanes 1 and 3), whereas the SMN2-derivedheptamer was much less efficient, behaving similarly to a BRCA1 naturalexon-skipping mutant (FIG. 16 b, lanes 2 and 4) and reflecting thedifferences in SF2/ASF heptamer motif scores.

An in vitro system to study SMN pre-mRNA splicing was developed. As theSMN1 and SMN2 minigenes used for transfection assays are too large forin vitro studies, internal deletions in introns 6 and 7, and 3′truncations in the non-coding exon 8 were made. Although exon 8 is thelast exon in the SMN genes, 10 nt were added which comprise a consensus5′ splice site at the 3′ end of the minigenes to improve the overallsplicing efficiency by exon definition. Several minigene transcript setswere tested, until a set that spliced in vitro with reasonableefficiency and faithfully reflected the inl vivo splicing patterns wasdefined (FIG. 17 and Methods below). The presence of the consensus 5′splice site at the 3′ end greatly increased splicing efficiency (datanot shown). An optimal set of four minigenes corresponding to SMN1,SMN2, and the A11G suppressor mutation in both contexts (FIG. 17 a) wastranscribed in vitro and spliced in HeLa cell nuclear extract. Exon7-containing mRNAs were the predominant spliced product with the SMN1substrate (55% inclusion; FIG. 17 b, lane 1), whereas exon 7 skippingwas favored with the C6T (SMN2) substrate (23% inclusion; FIG. 17 b,lane 2). In agreement with the transfection experiments (FIG. 11), theA11G suppressor mutation in the SMN2 context fully restored theinclusion levels observed with SMN1 (FIG. 17 b, lane 4; 65% inclusion).Significantly, the same mutation in the SMN1 context promoted exoninclusion with even higher efficiency than the wild type (FIG. 17 b,lane 3; 82% inclusion), consistent with the presence of a higher SF2/ASPmotif score (6.03 vs. 3.76).

Finally, splicing of SMN1 and SMN2 pre-mRNAs in S100-complementationexperiments was used to test the SR protein specificity of the ESEs.S100 extract is a post-nuclear, post-ribosomal fraction capable ofsupporting in vitro splicing only when complemented with one or more SRproteins. When the SMN pre-mRNAs were incubated in S100 extract alone,spliced products were barely detectable (FIG. 17 b, lanes 5-8).Complementation with SF2/ASF gave splicing patterns comparable to thoseobtained with nuclear extract (FIG. 17 b, lanes 9-12). In particular,SF2/ASF promoted exon 7 inclusion with SMN1 pre-mRNA (lane 9), but didso much less efficiently with SMN2 pre-mRNA (lane 10). As with nuclearextract, the A11G suppressor mutation significantly increased theinclusion efficiency in both SALV gene contexts (lanes 11 and 12). Thelevels of exon 7 inclusion depended on the dose of SF2/ASF, and, at highconcentrations, SF2/ASF promoted significant inclusion even in the SMN2context (data not shown). This result is consistent with the presence ofa second SF2/ASF high-score motif downstream in the exon, in a regionunaffected by the mutations (FIG. 9). In contrast to SF2/ASF,recombinant SC35 failed to drive exon 7 inclusion (FIG. 17 b, lanes13-16), even though it promoted splicing via exon 7 skipping (samelanes) and efficiently complemented S100 extract with β-globin pre-mRNA(data not shown), again indicating that the SC35 motif in exon 7 is nota functional ESE.

Example 7 Methods for Example 6

Minigenes and Templates. All SMN constructs were derived from pCITel.First, an Xba I site was inserted by site-directed mutagenesis atposition 7170 (in intron 7) to generate pCI-SMNx-wt, using a Quickchangekit (Stratagene) with primers smnI7xbaF(AGATAAAAGGTTAATCTAGATCCCTACTAGAATTCTC) (SEQ ID NO.: 18) and smnI7xbaR(GAGAATTCTAGTAGGGATCTAGATTAACCTTTTATCT) (SEQ ID NO: 19). PCI-SMNx-wt wasthen used as a template to generate the following constructs (mutantbases underlined): pCISMNx-c6t (primers smnM6ctF,ATTTTCCTTACAGGGTTTTAGACAAAATCAAAAAGAAG (SEQ ID NO: 20) and smnM6ctR,CTTCTTTTTGATTTTGTCTAAAACCCTGTAAGGAAAAT) (SEQ ID NO: 21), pCISMNx-c6a(primers smnM6caF,

-   -   ATTTTCCTTACAGGGTTTAAGACAAAATCAAAAAGAAG (SEQ ID NO: 22) and        smnM6caR, CTTCTTTTTGATTTTGTCTTAAACCCTGTAAGGAAAAT) (SEQ ID NO:        23), pCISMNx-c6g (primers smnM6cgF,    -   ATTTTCCTTACAGGGTTTGAGACAAAATCAAAAAGAAG (SEQ ID NO: 24) and        smnM6cgR, CTTCTTTTTGATTTTGTCTCAAACCCTGTAAGGAAAAT) (SEQ ID NO:        25), pCISMNx-a11g (primers smnM11agF,    -   ATTTTCCTTACAGGGTTTCAGACGAAATCAAAAAGAAG (SEQ ID NO: 26) and        sinM11agR, CTTCTTTTTGATTTCGTCTGAAACCCTGTAAGGAAAAT) (SEQ ID NO:        27), pCISMNx-c6t/a11g (primers srnnM6ct/11agF,    -   ATTTTCCTTACAGGGTTTTAGACGAAATCAAAAAGAAG (SEQ ID NO: 28) and        smnM6ct/11agR,    -   CTTCTTTTTGATTTCGTCTAAAACCCTGTAAGGAAAAT) (SEQ ID NO: 29),        pCISMNx-c6a/a11g (primers smnM6ca/11agF,    -   ATTTTCCTTACAGGGTTTAAGACGAAATCAAAAAGAAG (SEQ ID NO: 30) and        smnM6ca/11agR,    -   CTTCTTTTTGATTTCGTCTTAAACCCTGTAAGGAAAAT) (SEQ ID NO: 31),        pCISMNx-c6g/a11g (primers smnM6cg/11agF,    -   ATTTTCCTTACAGGGTTTGAGACGAAATCAAAAAGAAG (SEQ ID NO: 32) and        smnM6cg/11agR,    -   CTTCTTTTTGATTTCGTCTCAAACCCTGTAAGGAAAAT) (SEQ ID NO: 33).

Intron 6 was shortened by overlap-extension PCR to generatepCISMNxΔ6-wt. 5570 nt were deleted from position 1235 to the Bcl I siteat position 6805. Two sets of PCR were performed with Pfu polymerase andpCISMNx-wt as template. The first PCR was carried out with primers CIF1(AATTGCTAACGCAGTCAGTGCTTC) (SEQ ID NO: 34) and delta6-bclR(AATATGATCAGCAAAACAAAGTCACATAACTAC) (SEQ ID NO: 35), the second withprimers smnΔ6-vrlp (GTGACTTTGTTTTGCTGATCATATTTTGTTGAATAAAATAAG) (SEQ IDNO: 36) and CIR (AATGTATCTTATCATGTCTGCTCG) (SEQ ID NO: 37). The purifiedPCR products where then combined and reamplified with primers CIF1 andCIR. The final product was digested with Xho I and Not I and subclonedinto pCISMNx-wt digested with the same enzymes. The mutations wereintroduced into pCISMNxΔ6-wt by subeloning a Bcl I-Xba I fragmentcontaining part of intron 6, exon 7 and part of intron 7 from thefull-length mutants into the corresponding sites of the new vector, togenerate pCISMNxΔ6-c6t, pCISMNxΔ6-a11g, and pCISMNxΔ6-6/11. All theconstructs were verified by direct sequencing. To obtain templates forin vitro transcription, the latter four plasmids were amplified withprimers CIF2 (ACTTAATACGACTCACTATAGGCTAGCC) (SEQ ID NO: 38) andsmn8-75+5′R (AAGTACTTACCTGTAACGCTTCACATTCCAGATCTGTC) (SEQ ID NO: 39).The final products contain a T7 promoter, exon 6 (124 nt), a shortenedintron 6 (200 nt), wild-type or mutant exon 7 (54 nt), intron 7 (444nt), and 75 nt of exon 8 followed by a consensus 5′ ss. TheBRCA1-derived constructs were generated by overlap-extension PCR usingpBRCA1-WT as template. Primers T7P1(ref) and brSMI.R

-   -   (CAGTGTCCGTTCACACACATTGTCTGCATCTGCAGAATGAAAAACAC) (SEQ ID        NO: 40) or brSM2.R    -   (CAGTGTCCOTTCACACACATTGTCTACATCTGCAGAATGAAAAACAC) (SEQ ID        NO: 41) and primers brSM1.F    -   (GTGTTTTTCATTCTGCAGATGCAGACAATGTGTGTGAACGGACACTG) (SEQ ID        NO: 42) or brSM2.F    -   (GTGTTTTTCATTCTGCAGATGTAGACAATGTGTGTGAACGOACACTG) (SEQ ID        NO: 43) and P6(ref) were used in the first-step PCR, and T7P 1        and P6 were used in the second step. The purified PCR products        were directly used as transcription templates.

Transfections and Reverse-Transcription-PCR (RT-PCR). 293-HEK cells weretransiently transfected by standard Ca₃(PO₄)₂ procedures -with 10 μg ofthe indicated plasmids. 36 hours after transfection, total RNA wasisolated using Trizol Reagent (Life Technologies) following themanufacturer's directions. One μg of DNAse-treated total RNA was used togenerate first-strand cDNAs with oligo(dT) and Superscript II reversetranscriptase (Life Technologies), and cDNAs were amplifiedsemi-quantitatively by. 16 PCR cycles (94° C. for 30 sec, 57.5° C. for30 sec, 72° C. for 90 sec) using CIF2 and CIR primers in the presence of[α-³²P] dATP. The reaction products were resolved on 6% denaturingpolyacrylamide gels.

Example 8 It vitro Transcription and Splicing

5′ capped, T7 runoff transcripts from purified PCR products wereuniformly labeled with [α-³²P] UTP, purified by denaturing PAGE, andspliced in HeLa cell nuclear or S100 extracts, as described. Briefly, 10fmol of transcript was incubated in 12.5-μl standard splicing reactionscontaining 3 μl of nuclear extract or 2 μl of S100 extract complementedwith 4 pmol of recombinant SC35 or SF2/ASF. The MgCl₂ concentration was2.4 mM for BRCA1 transcripts and 1.6 mM for SMN transcripts. Afterincubation at 30° C. for 4 hours, RNA was extracted and analyzed on 12%(BRCA1) or 8% (SMN) denaturing polyacrylamide gels, followed byautoradiography and phosphorimager analysis. Exon inclusion wascalculated as a percentage of the total amount of spliced mRNAs, i.e.,included mRNA×100/(included mRNA+skipped mRNA).

Example 9 High-score Motif Analysis

Exon sequences from SMN1, SMN2, and mutants thereof, were analyzed asdescribed. For each SR protein, the highest score for each sequence in apool of 30 random 20-mers was calculated, and the median of these highscores was set as the threshold value for that SR protein The thresholdvalues are: SF2/ASF heptamer motif, 1.956; SRp40 heptamer motif, 2.670;SRp55 hexamer motif 2.676; SC35 octamer motif, 2.383. Scores below thethresholds are not considered significant.

Table 1 shows the alteration of enhancer motif scores by point mutationsin human genes. A database of 50 single-base substitutions responsiblefor in vivo exon skipping in 18 human genes was analyzed with the scorematrices for four SR proteins. Genes for which the mutation fallswithin, or creates, one or more high-score motifs are shown. Downwardarrows denote a reduction or elimination of the motif score as a resultof the mutation. Upward arrows denote a higher score in the mutant thanin the wild-type. Sequence motifs for the same or for a different SRprotein can overlap. Only the wild-type or mutant sequence motifs withscores greater than or equal to the threshold for the corresponding SRprotein were considered. Fourteen mutations that do not fall within, orcreate, high-score motifs for SF2/ASF, SRp40, SRp55, or SC35 are notshown; they are: ADA R142X, DYS E1211X, HPRTK55X, HPRT G119X, HPRTG180X, HPRT G180E, HPRT G180V, HPRT E182X, HPRT E182K, HPRT D201V, MNKG1302R, OAT W275X, PDH G185G, THY R717X. Thirty-six mutations fellwithin, or created, one or more high-score motifs, and 27 of thesemutations reduced or eliminated at least one high-score motif. There areover twice as many downward arrows (43) as upward arrows (21).N—nonsense mutation; M—missense mutation; S—synonymous mutation. Theexon with the mutation, which is also the exon skipped during splicing,is indicated (column labeled Mut). The specific mutations are identifiedby the wild-type amino acid in the one-letter code, followed by theresidue number in the protein sequence and the mutant amino acid (Xdenotes one of the three nonsense codons) as it would be in the absenceof exon skipping (column labeled Sub.). Gene abbreviations:ADA—adenosine deaminase; CFTR—cystic fibrosis transmembrane conductanceregulator; DYS—dystrophin; FVIII—factor VIII; FACC—Fanconi's anemiagroup C; FBN1—fibrillin; HEX—β-hexosaminidase β subunit;HMGCL—hydroxymethylglutaryl-CoA lyase; HPRT—hypoxanthinephosphoribosyltransferase; IDUA—α-L-iduronidase; MNK—Menkes disease;NF1—neurofibromatosis; OAT—ornithine δ-aminotransferase;PBG—porphobilinogen deaminase; PDH—pyruvate dehydrogenase; PS—protein S;THY—thyrroglobulin; WAS—Wiskott-Aldrich syndrome. TABLE 1 Gene Mut. Sub.Exon Type SF2/ASF SRp40 SRp55 SC35 CFTR E60X G→T 3 N → CFTR R75X C→T 3 N↓ CFTR R553X C→T 11 N ↑ CFTR W1282X G→A 20 N ↓↓ ↓ FVIII E1987X G→T 19 N↓ ↓ FVIII R2116X C→T 22 N ↑ FACC R185X C→T 6 N ↓ ↓↓ FBN1 Y2113X T→G 51 N↓ ↓ HMGCL E37X G→T 2 N ↑ HPRT E30X G→T 2 N ↓ ↓↑ HPRT E47X G→T 3 N ↑ HPRTR51X C→T 3 N ↓ HPRT C66X T→A 3 N ↑ ↓ HPRT K103X A→T 3 N ↓ ↑ ↓ HPRT L125XT→G 4 N ↓ HPRT E197X G→T 8 N ↑ ↓ HPRT Y198X C→G 8 N ↑↓ ↓ IDUA Y64X C→A 2N ↓ MNK R645X C→T 8 N ↓ NF1 Y2264X C→A 37 N ↓ NF1 Y2264X C→G 37 N ↓ OATW178X G→A 6 N ↓ ↓ PS S62X C→G 4 N ↑ WAS Q99X C→T 3 N ↓ ADA A215T G→A 7 M↑↑ ↑↑ HEX P404L C→T 11 M ↓ ↓ HPRT G40V G→T 2 M ↑ ↑ HPRT R48H G→A 3 M ↓HPRT A161E C→A 6 M ↓ ↓↑ ↓ HPRT P184L C→T 8 M ↓ ↑ ↓ HPRT D194Y G→T 8 M ↑↓ HPRT E197K G→A 8 M ↓ HPRT E197V A→T 8 M ↑ FBN1 I2118I C→T 51 S ↑ HPRTF199F C→T 8 S ↓ ↓ PBG R28R C→G 3 S ↓ ↓

Example 10 Specific Targeting of Double-stranded DNA by Bis-PNA in vitro

A gel-shift experiment shows that a PNA clamp binds specifically todouble-stranded DNA, and that the binding is sensitive to mutations atthe binding site. (See FIG. 18.) As expected, the binding is sensitiveto salt concentration and pH. For optimal binding under physiologicalconditions, a clamp in which C residues on the Hoogsteen strand arereplaced by pseudoisocytosine is used. Clamps with this substitution,with or without various attached transcription activation domains,modulate γ-globin transcription after delivery to K562 or HeLa cells.

Example 11 Expression of BRCA1 in Lymphoblast Cell Lines

PNA-RS chimeric molecules specific for BRCA1 exon 18 (FIG. 6), accordingto the invention, were introduced into transformed human lymphoblastsheterozygous for the mutant allele of BRCA1 that causes skipping of exon18. FIG. 19 shows that spliced mRNAs arising from exon 18 inclusion orskipping are present at comparable levels in these cells, whereashomozygous wild-type control cells only express mRNA that includes exon18. Delivery of the PNA-RS chimeric molecule results in a dose-dependentdisappearance of the lower band and increase in the intensity of theupper band.

1. A chimeric molecule comprising: a) a base-pairing segment that bindsspecifically to a single-stranded target nucleic acid molecule; and b) amoiety that modulates splicing and/or translation.
 2. A chimericmolecule according to claim 1 wherein said base-pairing segmentcomprises a non-sugar or a modified sugar backbone.
 3. A chimericmolecule according to claim 2 wherein said modified sugar backbonecomprises a 2′ O-methyl ribose group.
 4. A chimeric moleculeaccording,to claim 2 wherein said non-sugar backbone comprises apeptide-nucleic acid (PNA) segment.
 5. A chimeric molecule according toclaim 2 wherein said non-sugar backbone comprises morpholino groups. 6.A chimeric molecule according to claim 1 wherein said chimeric moleculehas a branched structure.
 7. A chimeric molecule according to claim 1wherein said base-pairing segment comprises about six to about fiftybases.
 8. A chimeric molecule according to claim 7 wherein saidbase-pairing segment comprises about ten to about thirty bases.
 9. Achimeric molecule according to claim 1 wherein said moiety is apolypeptide.
 10. A chimeric molecule according to claim 9 wherein saidpolypeptide comprises about five to about fifty residues.
 11. A chimericmolecule according to claim 9 wherein said polypeptide comprises aboutfifteen to about thirty residues.
 12. A chimeric molecule according toclaim 9 wherein said polypeptide comprises a domain involved in splicingactivation.
 13. A chimeric molecule according to claim 12 wherein saiddomain comprises dipeptide repeats.
 14. A chimeric molecule according toclaim 13 wherein said domain comprises arginine-serine dipeptiderepeats.
 15. A chimeric molecule according to claim 13 wherein saiddomain comprises arginine-glutamic acid dipeptide repeats.
 16. Achimeric molecule according to claim 15 wherein said domain comprisesabout five to about fifteen arginine-serine dipeptide repeats.
 17. Achimeric molecule according to claim 1 wherein said moiety is a secondnucleic acid molecule.
 18. A chimeric molecule according to claim 17wherein said second nucleic acid molecule comprises a binding site for asplicing protein.
 19. A chimeric molecule according to claim 18 whereinsaid splicing protein is endogenous.
 20. A chimeric molecule accordingto claim 1 comprising a spacer sequence between said base-pairingsegment and said moiety.
 21. A chimeric molecule according to claim 20wherein said spacer sequence comprises from about one to about twentyamino acid residues.
 22. A chimeric molecule according to claim 20wherein said spacer sequence consists of at least one glycine.
 23. Achimeric molecule according to claim 12 wherein said modulation ofsplicing is modulation of alternative splicing.
 24. A chimeric moleculeaccording to claim 12 wherein said single-stranded nucleic acid moleculeis a segment of pre-mRNA.
 25. A chimeric molecule according to claim 24wherein said segment of a pre-mRNA is an exon.
 26. A chimeric moleculeaccording to claim 24 wherein said segment of a pre-mRNA is an intron.27. A chimeric molecule according to claim 24 wherein said segment ofpre-mRNA comprises a mutation.
 28. A chimeric molecule according toclaim 27 wherein said segment of pre-mRNA is an exon of SAN2.
 29. Achimeric molecule according to claim 28 wherein said exon of SMN2 isexon
 7. 30. A chimeric molecule according to claim 9 wherein saidpolypetide is a translation activation domain.
 31. A chimeric moleculecomprising: a) a base-pairing segment that binds specifically to adouble-stranded nucleic acid molecule; and b) a peptide that modulatestranscription, wherein said peptide comprises up to about one hundredamino acid residues.
 32. A chimeric molecule according to claim 31wherein said peptide comprises from about ten to about thirty residues.33. A method for modulating splicing and/or translation comprising:contacting a single-stranded nucleic acid molecule with a chimericmolecule which comprises a) a base-pairing segment that specificallybinds to a portion of said single-stranded nucleic acid molecule; and b)a moiety that modulates said splicing and translation; whereby thebinding of the base-pairing segment allows the moiety to modulate saidsplicing and translation.
 34. A method according to claim 33 whereinsaid modulation is splicing and said single-stranded nucleic acidmolecule is a pre-mRNA transcript.
 35. A method according to claim 34wherein said chimeric molecule binds to said pre-mRNA transcript fromabout 0 to about 300 residues from a splice site on said pre-mRNAtranscript.
 36. A method according to claim 35 wherein said chimericmolecule binds to an intron of said pre-mRNA transcript.
 37. A methodaccording to claim 35 wherein said chimeric molecule binds to an exon ofsaid pre-mRNA transcript.
 38. A method according to claim 33 whereinsaid modulation of splicing is modulation of the rate of splicing.
 39. Amethod according to claim 33 wherein said modulation of splicing ismodulation of alternative splicing.
 40. A method according to claim 39wherein said modulation of alternative splicing increases the expressionof a gene.
 41. A method according to claim 33 wherein said modulation ofsplicing decreases the expression of a gene.
 42. A method according toclaim 41 wherein said modulation of splicing decreases the expression ofan oncogene or a viral gene.
 43. A method according to claim 33 whereinsaid modulation of splicing promotes inclusion of a target exon in amRNA transcript.
 44. A method according to claim 43 wherein an exonicsplicing enhancer of said target exon is absent or inactive.
 45. Amethod according to claim 44 wherein said exonic splicing enhancer ofsaid target exon is absent or inactive due to a nonsense mutation,missense mutation, synonymous mutation, frameshift mutation,intra-exonic deletion, intra-exonic insertion or single-nucleotidepolymorphism.
 46. A method according to claim 45 wherein said targetexon is an exon of SMN2.
 47. A method according to claim 46 wherein saidexon of SMN2 is exon
 7. 48. A method according to claim 47 wherein saidchimeric molecule is delivered to patients with spinal muscular atrophy.49. A method according to claim 47 wherein said chimeric molecule isdelivered in utero.
 50. A method according to claim 33 wherein saidsplicing does not occur naturally.
 51. A method to correct defectivesplicing of a pre-mRNA transcript during pre-mRNA splicing comprising:contacting said pre-mRNA transcript with a chimeric molecule comprisinga) a base-pairing segment that specifically binds to said pre-mRNAtranscript; and b) a moiety that modulates splicing; whereby the bindingof the base-pairing segment allows the moiety to correct defectivesplicing.
 52. A method for modulating transcription comprising:contacting a double-stranded nucleic acid molecule with a chimericmolecule which comprises a) a base-pairing segment that specificallybinds to a portion of said double-stranded nucleic acid molecule; and b)a moiety that modulates transcription; whereby the binding of thebase-pairing segment allows the peptide to modulate transcription.
 53. Amethod according to claim 52 wherein the moiety is a peptide thatmodulates transcription; wherein said peptide comprises from about twoto about one hundred amino acid residues.
 54. A method of making achimeric molecule comprising covalently bonding: a) a base-pairingsegment that binds specifically to a nucleic acid molecule; and b) amoiety that modulates gene expression; wherein a chimeric molecule ismade.